Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12065582 | 0.75 | PLCG1 (0.32) | — | |
| SCHEMBL18982315 | 0.72 | MMP8 (0.33) | MEN1KMT2A | |
| SCHEMBL19006348 | 0.71 | MEN1 (0.39) | ENPP3MEN1KMT2A | |
| SCHEMBL18214733 | 0.70 | ENPP3 (0.35) | ENPP3 | |
| SCHEMBL2656541 | 0.69 | ENPP3 (0.42) | ENPP3 | |
| SCHEMBL19006272 | 0.69 | DAO (0.33) | MEN1KMT2A | |
| SCHEMBL9980378 | 0.67 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL9987530 | 0.67 | PTPRB (0.38) | CYP2C19MEN1KMT2AHDAC3KCNN4 | |
| SCHEMBL18867386 | 0.66 | ENPP3 (0.35) | ENPP3 | |
| SCHEMBL286492 | 0.66 | DAGLA (0.43) | CYP2C19ENPP3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3079701-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2021-08-11 | — | — | EP | disclosed |
| US-9611278-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160304536-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | US | disclosed |
| EP-3079701-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2016-10-19 | — | — | EP | disclosed |
| US-9365574-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2575473-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015088885-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-18 | — | — | WO | disclosed |
| EP-2575473-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20130072492-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME LLC | 2013-03-21 | — | — | US | disclosed |
| WO-2011149921-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072492-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A2, GUCY1A1, PDE2A | CYP2C19 856/4885ENPP3 366/4885MEN1 1179/4885 |
| US-20160304536-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A1, GUCY1A2, PRKG1 | CYP2C19 999/4885ENPP3 423/4885MEN1 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.